Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers

Author(s):
Lunenburg, C.A.T.C.; Henricks, L.M.; Dreussi, E.; Peters, F.P.; Fiocco, M.; Meulendijks, D.; Toffoli, G.; Guchelaar, H.J.; Swen, J.J.; Cecchin, E.; Schellens, J.H.M.; Gelderblom, H.
Published
2018
Publication type
Article / Letter to editor
ChemoradiotherapyCapecitabineFluorouracilPharmacogeneticsToxicityDihydropyrimidine dehydrogenase
Date issued
2018-11-30
Language
English
Is part of
European Journal of Cancer (2018), Vol. 104, p. 210-218
hdl
1887/78441
doi
10.1016/j.ejca.2018.07.138